Acceder

Publicaciones - FARMACOCINETICA CLINICA Y FARMACOTERAPIA APLICADA

Cargando...
Diaz LS, Navalon CI, Espin RG, Prado IN, Redondo LR. Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2023 Aug-Sep;46(7):504-511. doi: 10.1016/j.gastrohep.2022.10.019. Epub 2022 Nov 15. English, Spanish. PubMed PMID: 36400260.
AÑO: 2023; IF: 1.9
36400260
Serrano-Diaz L, Iniesta-Navalon C, Gomez-Espin R, Nicolas-de Prado I, Bernal-Morell E, Rentero-Redondo L. Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach. Rev Esp Enferm Dig. 2023 Aug;115(8):435-443. doi: 10.17235/reed.2022.8781/2022. PubMed PMID: 36562529.
AÑO: 2023; IF: 2.0
36562529
Serrano Diaz L, Iniesta Navalon C, Gomez Espin R, Nicolas De Prado I, Bernal Morell E, Rentero Redondo L. Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study. Gastroenterol Hepatol. 2023 Aug 18:S0210-5705(23)00392-8. doi: 10.1016/j.gastrohep.2023.08.004. Online ahead of print. English, Spanish. PubMed PMID: 37597745.
AÑO: 2023; IF: 1.9
37597745
Gómez Espín R, Nicolás De Prado I, Gil Candel M, González Carrión M, Rentero Redondo L, Iniesta Navalón C. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study. Rev Esp Enferm Dig. 2021 Feb;113(2):110-115. doi: 10.17235/reed.2020.7124/2020. PubMed PMID: 33213170.
AÑO: 2021; IF: 2.389
33213170
Iniesta Navalón C, Gil Candel M, Salar Valverde I, Nicolás de Prado I, Gómez Espín R, Rentero Redondo L. Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival. Rev Esp Enferm Dig. 2021 Nov;113(11):770-775. doi: 10.17235/reed.2021.7638/2020. PubMed PMID: 33486961.
AÑO: 2021; IF: 2.389
33486961
Siguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

FARMACOCINETICA CLINICA Y FARMACOTERAPIA APLICADA